Pfizer Withheld Crucial Data In Lipitor Patent Filing, Ranbaxy Claims
By Marius Meland
Law360, New York (November 23, 2004, 12:00 AM EST) -- Pfizer Inc. withheld crucial scientific data that might have influenced the patent review board's decision to grant the drug maker a second patent for Lipitor, attorneys for Indian generics maker Ranbaxy Laboratories Ltd. argued at the opening of the closely watched trial over patent rights to the blockbuster anti-cholesterol drug.
“Ranbaxy does not make this challenge wildly. We realize it is a serious charge,” said Darrell Olson, of the intellectual-property specialty firm Knobbe, Martens, Olson & Bear LLP of Irvine California, representing Ranbaxy.